Literature DB >> 33600468

Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice.

Jenessa A Winston1, Alissa Rivera1, Jingwei Cai2, Andrew D Patterson2, Casey M Theriot1.   

Abstract

Ursodeoxycholic acid (commercially available as ursodiol) is a naturally occurring bile acid that is used to treat a variety of hepatic and gastrointestinal diseases. Ursodiol can modulate bile acid pools, which have the potential to alter the gut microbiota community structure. In turn, the gut microbial community can modulate bile acid pools, thus highlighting the interconnectedness of the gut microbiota-bile acid-host axis. Despite these interactions, it remains unclear if and how exogenously administered ursodiol shapes the gut microbial community structure and bile acid pool in conventional mice. This study aims to characterize how ursodiol alters the gastrointestinal ecosystem in conventional mice. C57BL/6J wildtype mice were given one of three doses of ursodiol (50, 150, or 450 mg/kg/day) by oral gavage for 21 days. Alterations in the gut microbiota and bile acids were examined including stool, ileal, and cecal content. Bile acids were also measured in serum. Significant weight loss was seen in mice treated with the low and high dose of ursodiol. Alterations in the microbial community structure and bile acid pool were seen in ileal and cecal content compared to pretreatment, and longitudinally in feces following the 21-day ursodiol treatment. In both ileal and cecal content, members of the Lachnospiraceae Family significantly contributed to the changes observed. This study is the first to provide a comprehensive view of how exogenously administered ursodiol shapes the healthy gastrointestinal ecosystem in conventional mice. Further studies to investigate how these changes in turn modify the host physiologic response are important.

Entities:  

Year:  2021        PMID: 33600468      PMCID: PMC7891722          DOI: 10.1371/journal.pone.0246161

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  62 in total

1.  Butyric acid induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells.

Authors:  M Mandal; D J Olson; T Sharma; R K Vadlamudi; R Kumar
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

Review 2.  Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling.

Authors:  Annika Wahlström; Petia Kovatcheva-Datchary; Marcus Ståhlman; Fredrik Bäckhed; Hanns-Ulrich Marschall
Journal:  Dig Dis       Date:  2017-03-01       Impact factor: 2.404

3.  Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases.

Authors:  Henri Duboc; Sylvie Rajca; Dominique Rainteau; David Benarous; Marie-Anne Maubert; Elodie Quervain; Ginette Thomas; Véronique Barbu; Lydie Humbert; Guillaume Despras; Chantal Bridonneau; Fabien Dumetz; Jean-Pierre Grill; Joëlle Masliah; Laurent Beaugerie; Jacques Cosnes; Olivier Chazouillères; Raoul Poupon; Claude Wolf; Jean-Maurice Mallet; Philippe Langella; Germain Trugnan; Harry Sokol; Philippe Seksik
Journal:  Gut       Date:  2012-09-19       Impact factor: 23.059

Review 4.  Cross-talk between bile acids and intestinal microbiota in host metabolism and health.

Authors:  Yang-fan Nie; Jun Hu; Xiang-hua Yan
Journal:  J Zhejiang Univ Sci B       Date:  2015-06       Impact factor: 3.066

5.  Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.

Authors:  R E Poupon; A M Bonnand; P E Queneau; C Trépo; D Vetter; J J Raabe; G Thieffin; D Larrey; J D Grangé; J P Capron; L Serfaty; Y Chrétien; M F St Marc Girardin; H Mathiex-Fortunet; E S Zafrani; J Guéchot; U Beuers; G Paumgartner; R Poupon
Journal:  Scand J Gastroenterol       Date:  2000-06       Impact factor: 2.423

6.  Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones.

Authors:  Sven Fischer; Iris Müller; Benedikta Z Zündt; Christoph Jüngst; Günther Meyer; Dieter Jüngst
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-03       Impact factor: 2.566

Review 7.  TGR5: a novel target for weight maintenance and glucose metabolism.

Authors:  Xiaosong Chen; Guiyu Lou; Zhipeng Meng; Wendong Huang
Journal:  Exp Diabetes Res       Date:  2011-06-21

8.  SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB.

Authors:  Elmar Pruesse; Christian Quast; Katrin Knittel; Bernhard M Fuchs; Wolfgang Ludwig; Jörg Peplies; Frank Oliver Glöckner
Journal:  Nucleic Acids Res       Date:  2007-10-18       Impact factor: 16.971

9.  Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.

Authors:  Michaela Mueller; Anders Thorell; Thierry Claudel; Pooja Jha; Harald Koefeler; Carolin Lackner; Bastian Hoesel; Guenter Fauler; Tatjana Stojakovic; Curt Einarsson; Hanns-Ulrich Marschall; Michael Trauner
Journal:  J Hepatol       Date:  2015-01-21       Impact factor: 30.083

Review 10.  The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics.

Authors:  Jason M Ridlon; Jasmohan S Bajaj
Journal:  Acta Pharm Sin B       Date:  2015-02-09       Impact factor: 11.413

View more
  2 in total

1.  Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease.

Authors:  Russell R Fling; Timothy R Zacharewski
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

Review 2.  Bile acids, gut microbiota and metabolic surgery.

Authors:  Jui Tu; Yangmeng Wang; Lihua Jin; Wendong Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-22       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.